Shionogi & Co. | Date: 2016-11-18
The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity.
Shionogi & Co. | Date: 2016-09-30
The present invention is related to a compound represented by formula (I) wherein R^(1 )is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is N(R^(3)), O, or S; Y is C(R^(4)), or N; Z is N(R^(7)), O, or S;
Shionogi & Co. and National Cerebral And Cardiovascular Center | Date: 2016-09-20
A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.
Shionogi & Co. and ViiV Healthcare | Date: 2016-10-11
The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein
Shionogi & Co. | Date: 2016-09-09
Stable crystalline forms of a compound represented by the formula (IA): an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.
Shionogi & Co. | Date: 2017-02-08
A process for preparing a compound represented by formula (Y1) or (Y2) [wherein R^(x) is an optionally substituted carbocyclyl lower alkyl, or the like] or a salt thereof, using a novel process for preparing a pyridone derivative represented by formula (X4) [wherein R^(1d) is hydrogen, halogen, or the like; R^(2d) is hydrogen, a lower alkyl optionally substituted with substituent E, or the like; R^(4d) is a lower alkyl optionally substituted with substituent E, or the like; and R^(6d) is a lower alkyl group optionally substituted with substituent group E].
Shionogi & Co. | Date: 2017-04-05
The present invention relates to a Sonogashira-Carbonylation reaction using two types of gas, as well as novel crystals which can control a heat of the said reaction and the process of producing the same. In addition, the present invention relates to a ligand (additive) to prevent the deactivation of a palladium catalyst.
University of Tokyo, Tohoku University and Shionogi & Co. | Date: 2017-01-04
The present invention provides a compound of formula (I), wherein R^(1), R^(2), R^(3), R^(4a), R^(4b), R^(5a) and R^(5b) are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.
Shionogi & Co. | Date: 2017-03-22
The present invention provides the following compound having anti-HIV activity of formula:^(1) is C, CR^(1A) or N;A^(2) is C, CR^(2A), or N;A^(3) is CR^(3A), CR^(3A)R^(3B), N, NR^(3c) O, S, SO, or SO_(2) ;A^(4) is CR^(4A), CR^(4A)R^(4B), N, NR^(4C) O, S, SO, or SO2;A^(5) is C, CR^(5A), or N;T^(1) ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle;R^(1) is halogen, cyano, nitro or -X^(1)-R^(11);R^(2) is substituted or unsubstituted alkyl and the like;n is 1 or 2;R^(3) is hydrogen, substituted or unsubstituted aromatic varbocyclyl;R^(4) is hydrogen or a carboxy protecting group;the other symbols are as specified in the description.
Shionogi & Co. | Date: 2017-04-19
The present invention is the following Amphotericin B derivative: